18 Dic New funding to expand Respiro
Amiko Digital Health announces the investment from strategic investors Sanner and Breed Reply
London, UK. Dec. 18, 2017 — Amiko Digital Health Limited (Amiko), a company that develops advanced medication sensor technologies and AI-powered digital health tools, today announced the closing of a new financing round, led by Sanner Ventures and Breed Reply.
The funds will be utilized to expand Respiro, Amiko’s innovative respiratory disease management platform, and support the company’s mission to upgrade the current standard of respiratory care. Respiro offers a platform of medication sensors and connected health tools, enabling real-time monitoring of medication use and patient health. At the core of the platform: Respiro Sense, the technology that powers the world’s most advanced medication sensors. Combined with respiratory devices such as inhalers, the sensors automatically track the patient’s inhalation profiles to record when and how well patients use their medication and to help monitor lung health.
“Sanner and Breed Reply strongly believe our mission to transform respiratory care through advanced sensor technologies and AI” said Duilio Macchi, Amiko CEO. “We are excited to receive this investment, as the commitment from these organisations will be key in the commercialisation of Respiro and of our medication sensors.”
“Amiko’s approach makes the most of AI and medication use data to transform the delivery of respiratory healthcare, enabling better outcomes and lower healthcare costs,” commented Emanuele Angelidis, CEO of Breed Reply. “We first invested in Amiko in 2016. Since, they’ve created breakthrough patent technology, launched amazing partnerships and worked with global health service companies, demonstrating the demand for their technology.”
“We believe that Respiro Sense has the potential to become the leading platform technology for connected inhalers” said Christian Schierholz, Venture Associate of Sanner Ventures. “Respiro is ideally suited for both add-on and integrated modules: it is cost-efficient, unobtrusive, compatible with most inhalers, and collects unique medication use and inhalation data to facilitate true medication adherence.”
About Amiko Digital Health Limited
Amiko develops advanced sensor technologies and AI powered mobile health solutions to assist healthcare professionals and empower patients to achieve better outcomes.
Founded in 2014, Amiko has headquarters in central London and ISO 13485 certified laboratories in Milan. Today, Amiko serves commercial, institutional, and individual customers in Italy, Germany, France, Spain, UK and the Netherlands, and is growing to become a global provider of advanced therapeutics data and digital disease management services, empowering patients, healthcare professionals, and payers to realize a shared vision of a digital health enabled future.
Amiko’s flagship product is Respiro, a connected platform that offers smart devices, applications and analytics to upgrade respiratory care, improve health outcomes and reduce cost of care. Respiro includes medication sensors that collect unique inhalation data, to help monitor compliance, lung function and disease progression. The sensors are bundled with a mobile application, hich receives this data via Bluetooth Low Energy and offers simple metrics and personalized support for improved disease control. The Respiro Platform includes a suite of professional oriented applications, designed to empower healthcare professionals with remote monitoring tools, AI-enabled therapy suggestions and data analytics for them to make smarter decisions, and personalize treatments to the needs of the patients. Respiro has been validated in laboratory and clinical settings with world-renowned key opinion leaders and shown to significantly improve medication use and health outcomes.
For more information, visit amiko.io
About Sanner Ventures
As corporate venture capital office, Sanner Ventures aims to explore new business areas and to invest in early-stage technology companies in the area of health and well-being. Sanner Ventures is devoted to products and solutions that help protect patient health and facilitate consumer engagement. For further information, please visit: www.sanner-ventures.com
About the Sanner Group
Based in Bensheim, Germany, the Sanner Group was founded in 1894 and is now in its fourth generation as a family-owned enterprise. Sanner develops and produces high-quality plastic packaging and drug delivery systems for pharmaceutical, medical and healthcare customers. The group gained international recognition for its desiccant know-how and innovative active packaging solutions. Today Sanner is present all over the world, amongst others in Germany, China, India and the U.S. The company produces over two billion plastic units each year for standard and customized packaging solutions. For further information, please visit: www.sanner-group.com
About Breed Reply
Breed Reply, Reply’s active operational investor, funds and supports the development of early-stage companies in the Internet of Things (IoT) in Europe and the USA. Based in London, with operational offices in Germany and Italy, Breed Reply supports entrepreneurs and young talent by quickly bringing new ideas to the market. This is done via three fundamental services: funding at early-stage level; active operational involvement with significant know how transfer of business, managerial and technological expertise; and go-to market support through the extensive Reply network. Breed Reply focuses on Health, Fitness & Wellness, Smart Building & Cities, Security, Industrial IoT, Big Data, Platforms, Drones. For further information, please visit: www.reply.com/en/breed-reply/HomePage